Arbaclofen is under clinical development by Allos Pharma and currently in Phase II for Unspecified Genetic Disorders. According to GlobalData, Phase II drugs for Unspecified Genetic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Arbaclofen LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Arbaclofen overview
Arbaclofen (STX-209) is under development for treatment of fragile X syndrome, 16p11.2 deletion syndrome and autism. The drug candidate is administered orally. STX-209 acts by targeting selective gamma-amino butyric acid type B (GABA-B) receptor. GABA (B) receptor is a G-protein coupled receptor (GPCR) that associates with a subset of G-proteins that in turn regulate specific ion channels and trigger cAMP cascades.
Allos Pharma overview
Allos Pharma is developing therapeutics for the treatment of neurodevelopmental disorders. The company is headquartered in Wilmington, Delaware, the US.
For a complete picture of Arbaclofen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
